Publications by authors named "Regina GroSSe"
Article Synopsis
- Some breast cancer patients don’t fully respond to treatment, which makes it harder for them to recover.
- Researchers looked at a special biopsy method called VAB to see if it could help detect these patients before surgery.
- They found that VAB always showed if there was leftover cancer after treatment, while regular imaging methods weren't as reliable.
In accordance with article 20 of Regulation (EC) No 726/2004, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has re-evaluated the safety of Janus kinase inhibitors for the treatment of inflammatory diseases and formulated safety information deviating from the previous indications in the respective summary of product characteristics of the products concerned. These refer to the consideration of a possibly increased risk of venous thromboembolic or severe cardiovascular events, an increased infection rate and an increase in the prevalence of skin cancer across drugs and indications. Therefore, in patients with independent risk factors (age 65 years and older, smokers or former smokers, patients with oral contraception or hormone replacement therapy and other risk factors), it is recommended to use Janus kinase inhibitors therapeutically only if there are no suitable treatment alternatives.
View Article and Find Full Text PDFPurpose: Neoadjuvant systemic treatment (NST) elicits a pathologic complete response in 40%-70% of women with breast cancer. These patients may not need surgery as all local tumor has already been eradicated by NST. However, nonsurgical approaches, including imaging or vacuum-assisted biopsy (VAB), were not able to accurately identify patients without residual cancer in the breast or axilla.
View Article and Find Full Text PDFObjective: We evaluated the ability of minimally invasive, image-guided vacuum-assisted biopsy (VAB) to reliably diagnose a pathologic complete response in the breast (pCR-B).
Summary Background Data: Neoadjuvant systemic treatment (NST) elicits a pathologic complete response in up to 80% of women with breast cancer. In such cases, breast surgery, the gold standard for confirming pCR-B, may be considered overtreatment.
Introduction: It is generally accepted that estrogens play a protective role in cognitive function. Therefore, it can be expected that subtotal estrogen deprivation following aromatase inhibition will alter cognitive performance.
Methods: In a cross-sectional study we investigated 80 postmenopausal women with breast cancer.
Article Synopsis
- Neoadjuvant chemotherapy (NACT) is common in breast cancer treatment, aiming for a pathological complete response (pCR), but predicting pCR remains challenging; this study examines the role of minimal invasive biopsy (MIB) techniques in accurately diagnosing pCR in patients who show a clinical complete response (cCR) after NACT.
- A total of 164 patients were analyzed using core-cut (CC)-MIB or vacuum-assisted biopsy (VAB) after NACT; the study focused on negative predictive values (NPV) and false-negative rates (FNR) as primary measures to assess the accuracy of these biopsies in predicting pCR.
- The results indicated that while overall diagnostic accuracy for
Background: A regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) is superior to a regimen of fluorouracil, doxorubicin, and cyclophosphamide (FAC) when used as adjuvant therapy in women with node-positive breast cancer. The value of taxanes in the treatment of node-negative disease has not been determined.
Methods: We randomly assigned 1060 women with axillary-node-negative breast cancer and at least one high-risk factor for recurrence (according to the 1998 St.